Tharimmune, Inc. announced the filing of a definitive proxy statement (DEF 14A) with the U.S. Securities and Exchange Commission, detailing the upcoming annual meeting of stockholders scheduled for May 14, 2024. The meeting will address several key proposals, including the election of five board members, ratification of the independent accounting firm Rosenberg Rich Baker Berman P.A. for the fiscal year ending December 31, 2024, and approval of the Amended and Restated 2023 Omnibus Equity Incentive Plan. Additionally, the board will seek discretionary authority to amend the company's Certificate of Incorporation to effect a reverse stock split of the issued and outstanding shares of common stock, with a ratio range from 1-for-2 up to 1-for-50, to be completed by May 14, 2025. The reverse stock split...Show More

Tharimmune, Inc. announced the filing of a definitive proxy statement (DEF 14A) with the U.S. Securities and Exchange Commission, detailing the upcoming annual meeting of stockholders scheduled for May 14, 2024. The meeting will address several key proposals, including the election of five board members, ratification of the independent accounting firm Rosenberg Rich Baker Berman P.A. for the fiscal year ending December 31, 2024, and approval of the Amended and Restated 2023 Omnibus Equity Incentive Plan. Additionally, the board will seek discretionary authority to amend the company's Certificate of Incorporation to effect a reverse stock split of the issued and outstanding shares of common stock, with a ratio range from 1-for-2 up to 1-for-50, to be completed by May 14, 2025. The reverse stock split aims to increase the per-share price of Tharimmune's common stock to comply with Nasdaq's minimum bid price requirement. The board may also arrange for the disposition of fractional shares by rounding up to the next whole number. The meeting will also cover other business as may properly come before the meeting or any adjournment or postponement thereof.